Cambrex has positioned our product and custom development pipelines to leverage our API, drug delivery and formulation capabilities to develop technology advanced products. Our diverse small molecule portfolio helps us to expand into growing developing markets and advance our niche products and technologies.
Cambrex has transformed from a fine chemical manufacturer since its creation in 1981 – and we continue to pursue acquisitions and partnerships that improve the utilization of our manufacturing facilities, lower our cost structure and provide access to value added tools or IP and low cost R&D. This results in Cambrex being a streamlined business with singular focus on small molecule therapeutics.
Growth in the Life Sciences
2010 to Present
2010
To broaden biocatalysis and NRT offerings to the pharmaceutical industry, Cambrex acquires IEP GmbH; now Cambrex IEP and Zenara Pharma, Ltd; now Cambrex Zenara.
2000 to 2009
2009
Cambrex Karlskoga completes the addition of a new cGMP API production facility.
2008
Cambrex expands their group of world class R&D chemists by acquiring Prosyntest; renamed Cambrex Tallinn. Steven M. Klosk is appointed to CEO while remaining President. Cambrex Charles City completes the addition of a high potency development center.
2007
Cambrex exits the biologics market and re-focuses on small molecule APIs and intermediates at its three manufacturing facilities: Cambrex Karlskoga, Cambrex Profarmaco, and Cambrex Charles City. Cambrex Profarmaco completes the expansion of the R&D lab and the additions of a new purification department and warehouse.
2003
The company dedicates itself to providing essential products and services that accelerate drug discovery, development and manufacturing of human therapeutics.
2002
To support the Company's strategic emphasis on the growing opportunities in the life sciences industry, Cambrex launches a new corporate identity. Cambrex obtains DEA licensing for Controlled Substance API manufacturing.
2001
Cambrex enters the biologics manufacturing market with the acquisition of two contract biopharmaceutical manufacturing facilities. The facilities produce purified bulk biologics and pharmaceutical ingredients from clinical to commercial scale.
2000
Cambrex continues its growth into the life sciences and biologics industries through the acquisitions of a chiral enzymatic catalyst business and a bioscience products facility in Belgium.
1990 to 1999
1999
Cambrex enters the growing fields of molecular biology and proteomics through the acquisition of the FMC Bioproducts business. In addition to bioscience, this acquisition further strengthens the API and advanced intermediates manufacturing capacity.
1997
Cambrex enters the biologics markets with the acquisition of BioWhittaker, a life sciences company that provides cell culture and endotoxin detection products.
1994
Cambrex further penetrates the pharmaceutical market with the acquisition of the Nobel Pharma Chemistry businesses, Nobel Chemicals AB and Profarmaco S.r.l. The business units are later renamed Cambrex Karlskoga and Cambrex Profarmaco.
1991
The Company enters the life sciences arena with the acquisition of Salsbury Chemicals, a manufacturer of bulk intermediates and APIs, as well as high-level research in nitration chemistry, and Zeeland Chemicals, producer of specialty intermediates and hydrogenation chemistry.
1990
James A. Mack is hired as President and CEO. Cambrex is listed on the New York Stock Exchange (NYSE).
1980 to 1989
1987
The Company changes its name to Cambrex Corporation and becomes listed on the NASDAQ.
1981
Originally named CasChem, the Company is founded when the castor oil and derivatives product lines are acquired from NL Industries.
